Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Research Report 2024

Report ID: 1987306 | Published Date: Jan 2025 | No. of Page: 99 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Overview
    1.1 Product Overview and Scope of Oculopharyngeal Muscular Dystrophy (OPMD)
    1.2 Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Type
        1.2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth Rate Comparison By Type (2022-2028)
        1.2.2 Tablets
        1.2.3 Capsules
        1.2.4 Injectable
        1.2.5 Other
    1.3 Oculopharyngeal Muscular Dystrophy (OPMD) Segment By Application
        1.3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Comparison By Application: (2022-2028)
        1.3.2 Hospital Pharmacies
        1.3.3 Retail Pharmacies
        1.3.4 Online Pharmacies
    1.4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size Estimates and Forecasts
        1.4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue 2017-2028
        1.4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales 2017-2028
        1.4.3 Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Region: 2017 Versus 2021 Versus 2028
2 Oculopharyngeal Muscular Dystrophy (OPMD) Market Competition by Manufacturers
    2.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Sites, Area Served, Product Type
    2.5 Oculopharyngeal Muscular Dystrophy (OPMD) Market Competitive Situation and Trends
        2.5.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Oculopharyngeal Muscular Dystrophy (OPMD) Players Market Share by Revenue
        2.5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oculopharyngeal Muscular Dystrophy (OPMD) Retrospective Market Scenario by Region
    3.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
        3.3.1 North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country
        3.3.2 North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country
        3.3.3 United States
        3.3.4 Canada
    3.4 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
        3.4.1 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country
        3.4.2 Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Region
        3.5.1 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region
        3.5.2 Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 China Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
    3.6 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
        3.6.1 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country
        3.6.2 Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Market Facts & Figures by Country
        3.7.1 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country
        3.7.2 Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Oculopharyngeal Muscular Dystrophy (OPMD) Historic Market Analysis By Type
    4.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
    4.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Type (2017-2022)
    4.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Type (2017-2022)
5 Global Oculopharyngeal Muscular Dystrophy (OPMD) Historic Market Analysis By Application
    5.1 Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
    5.2 Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share By Application (2017-2022)
    5.3 Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Application (2017-2022)
6 Key Companies Profiled
    6.1 Benitec Biopharma Inc.
        6.1.1 Benitec Biopharma Inc. Corporation Information
        6.1.2 Benitec Biopharma Inc. Description and Business Overview
        6.1.3 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.1.5 Benitec Biopharma Inc. Recent Developments/Updates
    6.2 Bioblast Pharma
        6.2.1 Bioblast Pharma Corporation Information
        6.2.2 Bioblast Pharma Description and Business Overview
        6.2.3 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.2.5 Bioblast Pharma Recent Developments/Updates
    6.3 BioMarin
        6.3.1 BioMarin Corporation Information
        6.3.2 BioMarin Description and Business Overview
        6.3.3 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.3.5 BioMarin Recent Developments/Updates
    6.4 PTC Therapeutics
        6.4.1 PTC Therapeutics Corporation Information
        6.4.2 PTC Therapeutics Description and Business Overview
        6.4.3 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.4.5 PTC Therapeutics Recent Developments/Updates
    6.5 NS Pharma
        6.5.1 NS Pharma Corporation Information
        6.5.2 NS Pharma Description and Business Overview
        6.5.3 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.5.5 NS Pharma Recent Developments/Updates
    6.6 Nobelpharma Co., Ltd
        6.6.1 Nobelpharma Co., Ltd Corporation Information
        6.6.2 Nobelpharma Co., Ltd Description and Business Overview
        6.6.3 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.6.5 Nobelpharma Co., Ltd Recent Developments/Updates
    6.7 Santhera Pharmaceuticals
        6.6.1 Santhera Pharmaceuticals Corporation Information
        6.6.2 Santhera Pharmaceuticals Description and Business Overview
        6.6.3 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.7.5 Santhera Pharmaceuticals Recent Developments/Updates
    6.8 Pfizer Inc.
        6.8.1 Pfizer Inc. Corporation Information
        6.8.2 Pfizer Inc. Description and Business Overview
        6.8.3 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.8.5 Pfizer Inc. Recent Developments/Updates
    6.9 Marathon Pharmaceuticals
        6.9.1 Marathon Pharmaceuticals Corporation Information
        6.9.2 Marathon Pharmaceuticals Description and Business Overview
        6.9.3 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.9.5 Marathon Pharmaceuticals Recent Developments/Updates
    6.10 Fibrogen
        6.10.1 Fibrogen Corporation Information
        6.10.2 Fibrogen Description and Business Overview
        6.10.3 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.10.5 Fibrogen Recent Developments/Updates
    6.11 Bristol-Myers Squibb
        6.11.1 Bristol-Myers Squibb Corporation Information
        6.11.2 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Description and Business Overview
        6.11.3 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.11.5 Bristol-Myers Squibb Recent Developments/Updates
    6.12 Sarepta Therapeutics
        6.12.1 Sarepta Therapeutics Corporation Information
        6.12.2 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Description and Business Overview
        6.12.3 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.12.5 Sarepta Therapeutics Recent Developments/Updates
    6.13 GSK
        6.13.1 GSK Corporation Information
        6.13.2 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Description and Business Overview
        6.13.3 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product Portfolio
        6.13.5 GSK Recent Developments/Updates
7 Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Cost Analysis
    7.1 Oculopharyngeal Muscular Dystrophy (OPMD) Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
    7.4 Oculopharyngeal Muscular Dystrophy (OPMD) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Oculopharyngeal Muscular Dystrophy (OPMD) Distributors List
    8.3 Oculopharyngeal Muscular Dystrophy (OPMD) Customers
9 Oculopharyngeal Muscular Dystrophy (OPMD) Market Dynamics
    9.1 Oculopharyngeal Muscular Dystrophy (OPMD) Industry Trends
    9.2 Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers
    9.3 Oculopharyngeal Muscular Dystrophy (OPMD) Market Challenges
    9.4 Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints
10 Global Market Forecast
    10.1 Oculopharyngeal Muscular Dystrophy (OPMD) Market Estimates and Projections By Type
        10.1.1 Global Forecasted Sales of Oculopharyngeal Muscular Dystrophy (OPMD) By Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Oculopharyngeal Muscular Dystrophy (OPMD) By Type (2023-2028)
    10.2 Oculopharyngeal Muscular Dystrophy (OPMD) Market Estimates and Projections By Application
        10.2.1 Global Forecasted Sales of Oculopharyngeal Muscular Dystrophy (OPMD) By Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Oculopharyngeal Muscular Dystrophy (OPMD) By Application (2023-2028)
    10.3 Oculopharyngeal Muscular Dystrophy (OPMD) Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Oculopharyngeal Muscular Dystrophy (OPMD) by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Oculopharyngeal Muscular Dystrophy (OPMD) by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables
    Table 1. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth Rate Comparison By Type (2022-2028) & (K Units) & (US$ Million)
    Table 2. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Growth Rate Comparison By Application (2022-2028) & (K Units) & (US$ Million)
    Table 3. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units) of Key Manufacturers (2017-2022)
    Table 6. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Oculopharyngeal Muscular Dystrophy (OPMD) Average Price (US$/Unit) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Manufacturing Sites and Area Served
    Table 11. Manufacturers Oculopharyngeal Muscular Dystrophy (OPMD) Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oculopharyngeal Muscular Dystrophy (OPMD) as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2022) & (K Units)
    Table 16. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2017-2022)
    Table 17. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2017-2022)
    Table 19. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
    Table 20. North America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2017-2022)
    Table 21. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2017-2022)
    Table 23. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
    Table 24. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2017-2022)
    Table 25. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Region (2017-2022) & (K Units)
    Table 28. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
    Table 32. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2017-2022)
    Table 33. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales by Country (2017-2022) & (K Units)
    Table 36. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Country (2017-2022)
    Table 39. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales By Type (2017-2022) & (K Units)
    Table 40. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Type (2017-2022)
    Table 41. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Type (2017-2022) & (US$ Million)
    Table 42. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share By Type (2017-2022)
    Table 43. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Type (2017-2022) & (US$/Unit)
    Table 44. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units) By Application (2017-2022)
    Table 45. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share By Application (2017-2022)
    Table 46. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue By Application (2017-2022) & (US$ Million)
    Table 47. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share By Application (2017-2022)
    Table 48. Global Oculopharyngeal Muscular Dystrophy (OPMD) Price By Application (2017-2022) & (US$/Unit)
    Table 49. Benitec Biopharma Inc. Corporation Information
    Table 50. Benitec Biopharma Inc. Description and Business Overview
    Table 51. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 52. Benitec Biopharma Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 53. Benitec Biopharma Inc. Recent Developments/Updates
    Table 54. Bioblast Pharma Corporation Information
    Table 55. Bioblast Pharma Description and Business Overview
    Table 56. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 57. Bioblast Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 58. Bioblast Pharma Recent Developments/Updates
    Table 59. BioMarin Corporation Information
    Table 60. BioMarin Description and Business Overview
    Table 61. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 62. BioMarin Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 63. BioMarin Recent Developments/Updates
    Table 64. PTC Therapeutics Corporation Information
    Table 65. PTC Therapeutics Description and Business Overview
    Table 66. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 67. PTC Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 68. PTC Therapeutics Recent Developments/Updates
    Table 69. NS Pharma Corporation Information
    Table 70. NS Pharma Description and Business Overview
    Table 71. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 72. NS Pharma Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 73. NS Pharma Recent Developments/Updates
    Table 74. Nobelpharma Co., Ltd Corporation Information
    Table 75. Nobelpharma Co., Ltd Description and Business Overview
    Table 76. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 77. Nobelpharma Co., Ltd Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 78. Nobelpharma Co., Ltd Recent Developments/Updates
    Table 79. Santhera Pharmaceuticals Corporation Information
    Table 80. Santhera Pharmaceuticals Description and Business Overview
    Table 81. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 82. Santhera Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 83. Santhera Pharmaceuticals Recent Developments/Updates
    Table 84. Pfizer Inc. Corporation Information
    Table 85. Pfizer Inc. Description and Business Overview
    Table 86. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 87. Pfizer Inc. Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 88. Pfizer Inc. Recent Developments/Updates
    Table 89. Marathon Pharmaceuticals Corporation Information
    Table 90. Marathon Pharmaceuticals Description and Business Overview
    Table 91. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 92. Marathon Pharmaceuticals Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 93. Marathon Pharmaceuticals Recent Developments/Updates
    Table 94. Fibrogen Corporation Information
    Table 95. Fibrogen Description and Business Overview
    Table 96. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 97. Fibrogen Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 98. Fibrogen Recent Developments/Updates
    Table 99. Bristol-Myers Squibb Corporation Information
    Table 100. Bristol-Myers Squibb Description and Business Overview
    Table 101. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 102. Bristol-Myers Squibb Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 103. Bristol-Myers Squibb Recent Developments/Updates
    Table 104. Sarepta Therapeutics Corporation Information
    Table 105. Sarepta Therapeutics Description and Business Overview
    Table 106. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 107. Sarepta Therapeutics Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 108. Sarepta Therapeutics Recent Developments/Updates
    Table 109. GSK Corporation Information
    Table 110. GSK Description and Business Overview
    Table 111. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 112. GSK Oculopharyngeal Muscular Dystrophy (OPMD) Product
    Table 113. GSK Recent Developments/Updates
    Table 114. Production Base and Market Concentration Rate of Raw Material
    Table 115. Key Suppliers of Raw Materials
    Table 116. Oculopharyngeal Muscular Dystrophy (OPMD) Distributors List
    Table 117. Oculopharyngeal Muscular Dystrophy (OPMD) Customers List
    Table 118. Oculopharyngeal Muscular Dystrophy (OPMD) Market Trends
    Table 119. Oculopharyngeal Muscular Dystrophy (OPMD) Market Drivers
    Table 120. Oculopharyngeal Muscular Dystrophy (OPMD) Market Challenges
    Table 121. Oculopharyngeal Muscular Dystrophy (OPMD) Market Restraints
    Table 122. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast By Type (2023-2028) & (K Units)
    Table 123. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast By Type (2023-2028)
    Table 124. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast By Type (2023-2028) & (US$ Million)
    Table 125. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast By Type (2023-2028)
    Table 126. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast By Application (2023-2028) & (K Units)
    Table 127. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast By Application (2023-2028)
    Table 128. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast By Application (2023-2028) & (US$ Million)
    Table 129. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast By Application (2023-2028)
    Table 130. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Forecast by Region (2023-2028) & (K Units)
    Table 131. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share Forecast by Region (2023-2028)
    Table 132. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 133. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share Forecast by Region (2023-2028)
    Table 134. Research Programs/Design for This Report
    Table 135. Key Data Information from Secondary Sources
    Table 136. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Oculopharyngeal Muscular Dystrophy (OPMD)
    Figure 2. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share By Type in 2021 & 2028
    Figure 3. Tablets Product Picture
    Figure 4. Capsules Product Picture
    Figure 5. Injectable Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Share By Application in 2021 & 2028
    Figure 8. Hospital Pharmacies
    Figure 9. Retail Pharmacies
    Figure 10. Online Pharmacies
    Figure 11. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Oculopharyngeal Muscular Dystrophy (OPMD) Market Size (2017-2028) & (US$ Million)
    Figure 13. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales (2017-2028) & (K Units)
    Figure 14. Oculopharyngeal Muscular Dystrophy (OPMD) Sales Share by Manufacturers in 2021
    Figure 15. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Share by Manufacturers in 2021
    Figure 16. The Global 5 and 10 Largest Oculopharyngeal Muscular Dystrophy (OPMD) Players: Market Share by Revenue in 2021
    Figure 17. Oculopharyngeal Muscular Dystrophy (OPMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 18. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region (2017-2022)
    Figure 19. Global Oculopharyngeal Muscular Dystrophy (OPMD) Sales Market Share by Region in 2021
    Figure 20. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region (2017-2022)
    Figure 21. Global Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Market Share by Region in 2021
    Figure 22. United States Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 23. Canada Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. Germany Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. France Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. U.K. Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. Italy Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. Russia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. China Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. Japan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. South Korea Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. India Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. Australia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. China Taiwan Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Indonesia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Thailand Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Malaysia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Mexico Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Brazil Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Argentina Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Turkey Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Saudi Arabia Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. UAE Oculopharyngeal Muscular Dystrophy (OPMD) Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. Sales Market Share of Oculopharyngeal Muscular Dystrophy (OPMD) By Type (2017-2022)
    Figure 45. Manufacturing Cost Structure of Oculopharyngeal Muscular Dystrophy (OPMD)
    Figure 46. Manufacturing Process Analysis of Oculopharyngeal Muscular Dystrophy (OPMD)
    Figure 47. Oculopharyngeal Muscular Dystrophy (OPMD) Industrial Chain Analysis
    Figure 48. Channels of Distribution
    Figure 49. Distributors Profiles
    Figure 50. Bottom-up and Top-down Approaches for This Report
    Figure 51. Data Triangulation
    Figure 52. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
Frequently Asked Questions
Oculopharyngeal Muscular Dystrophy (OPMD) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Oculopharyngeal Muscular Dystrophy (OPMD) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Oculopharyngeal Muscular Dystrophy (OPMD) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports